

Structured Type 1 Diabetes Education Delivered Within Routine Care

Impact on glycemic control and diabetes-specific quality of life

DEBBIE COOKE, PHD¹
 ROD BOND, PHD²
 JULIA LAWTON, PHD³
 DAVID RANKIN, PHD³
 SIMON HELLER, MD⁴

MARIE CLARK, PHD⁵
 JANE SPEIGHT, PHD^{6,7,8}
 FOR THE U.K. NIHR DAFNE STUDY
 GROUP

OBJECTIVE—To determine whether improvements in glycemic control and diabetes-specific quality of life (QoL) scores reported in research studies for the type 1 diabetes structured education program Dose Adjustment For Normal Eating (DAFNE) are also found when the intervention is delivered within routine U.K. health care.

RESEARCH DESIGN AND METHODS—Before and after evaluation of DAFNE to assess impact on glycemic control and QoL among 262 adults with type 1 diabetes.

RESULTS—There were significant improvements in HbA_{1c} from baseline to 6 and 12 months (from 9.1 to 8.6 and 8.8%, respectively) in a subgroup with suboptimal control. QoL was significantly improved by 3 months and maintained at both follow-up points.

CONCLUSIONS—Longer-term improved glycemic control and QoL is achievable among adults with type 1 diabetes through delivery of structured education in routine care, albeit with smaller effect sizes than reported in trials.

Diabetes Care 36:270–272, 2013

Self-management training for type 1 diabetes on the model of the Düsseldorf structured teaching and treatment program (STTP) (1) has demonstrated a wide range of positive health and psychological outcomes within randomized controlled trials (RCTs) (1–3), and these effects are maintained wholly or in part in the longer term (4). These programs evolved in response to studies demonstrating benefits of intensified insulin therapy (5,6).

Eligibility criteria used within RCT mean trial populations may be unrepresentative (7). We aimed to determine whether improvements in glycemic control and

quality of life (QoL) reported in RCTs of self-management training are found when the program is delivered in routine U.K. health care.

RESEARCH DESIGN AND METHODS

Adults with type 1 diabetes were recruited, consecutively, from 73 courses at 12 U.K. hospitals, representing well-established ($n = 8$) and new centers ($n = 4$). The Dose Adjustment For Normal Eating (DAFNE) was selected as an exemplar of an STTP that has achieved widespread adoption by service providers. Efficacy has been demonstrated, obviating the need for a control group (2).

DAFNE comprises a 5-day course with booster session 6 weeks later, delivered to groups of up to eight by two trained diabetes educators. It promotes flexible, intensive, insulin therapy, separating basal from prandial rapid-acting insulin, and a flexible, varied diet with no forbidden foods. Dose adjustment depends on preprandial and bedtime blood glucose values. DAFNE is based on social learning theory (8). The main topics are carbohydrate counting and dose adjustment, along with managing hypoglycemia and illness. Eligibility criteria for course enrolment were applied as follows: 1) type 1 diabetes for at least 6 months, 2) >17 years of age, 3) absence of end-stage complications (e.g., renal failure), and 4) multiple daily injections

HbA_{1c} data were collected from routine records up to 8 weeks before and 6 and 12 months after the course. Participants completed the Diabetes-Specific Quality of Life Scale (DSQOLS) (9), before course enrollment and 3, 6, and 12 months after completion. Follow-up coincided with points at which HbA_{1c} was routinely determined in outpatients. The 3-month follow-up was included to allow sufficient time to observe short-term changes in QoL. The DSQOLS was designed to evaluate the Düsseldorf STTP, on which DAFNE is based. Psychometric validation of the scale in English used data from this study and two others (10,11) and will be reported elsewhere. The DSQOLS includes 57 items that form six subscales summed to gain a total score. Higher scores indicate better QoL.

RESULTS—Of 474 patients approached, 262 (55%) participated. Basic data, maintaining anonymity, permitted a comparison between participants ($n = 262$) and those who declined or were could not be contacted ($n = 254$). Non-participants had slightly higher baseline HbA_{1c} ($8.8 \pm 1.6\%$ vs. $8.5 \pm 1.5\%$ or 73 ± 18 mmol/mol vs. 69 ± 16 mmol/mol; $P = 0.02$).

DSQOLS response rate was 74% at each time point. HbA_{1c} data were available for 78% of participants at 6 months

From the ¹School of Health & Social Care, University of Surrey, Guildford, Surrey, U.K.; the ²School of Psychology, University of Sussex, Brighton, U.K.; the ³Centre for Population Health Sciences, Edinburgh University, Edinburgh, U.K.; the ⁴Academic Unit of Diabetes, University of Sheffield, Sheffield, U.K.; ⁵Epidemiology & Public Health, University College London, London, U.K.; ⁶AHP Research, Hornchurch, U.K.; ⁷The Australian Centre for Behavioural Research in Diabetes, Melbourne, Victoria, Australia; and the ⁸Centre for Mental Health and Wellbeing Research, School of Psychology, Deakin University, Burwood, Victoria, Australia.

Corresponding author: Debbie Cooke, debbie.cooke@ucl.ac.uk.

Received 13 January 2012 and accepted 2 August 2012.

DOI: 10.2337/dc12-0080

The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

and 93% at 12 months. There was no sex imbalance. Average age was 40 ± 14 years (range, 17–73 years); mean duration of diabetes was 18 \pm 13 years (range, 6 months–55 years); 89% were white British; 44% had a degree; 49% were in professional or managerial occupations; 61% were in full-time employment; and 68% were in a significant relationship. Mean baseline HbA_{1c} was $8.5 \pm 1.5\%$ (70 ± 16 mmol/mol), ranging from 5.4–14.2% (36–132 mmol/mol). A quarter ($n = 65$) had an HbA_{1c} level $<7.5\%$ (<58 mmol/mol), which was regarded as acceptable because further improvement would increase the risk of severe hypoglycemia. This subgroup was excluded from an analysis of people with suboptimal HbA_{1c}.

Linear mixed models were run with direct maximum likelihood to account for missing data. For HbA_{1c} in the total group, there was significant improvement from baseline to 6 months ($P < 0.001$) (Table 1), which was maintained at 12 months ($P < 0.001$), although there was a slight deterioration from 6 to 12 months ($P < 0.05$). In the subgroup with an HbA_{1c} level $\geq 7.5\%$, there was a clinically and statistically significant improvement in HbA_{1c} from baseline to both follow-up points (6 months, $P < 0.0001$; 12 months, $P < 0.01$), which

also showed a slight deterioration from 6 to 12 months ($P < 0.001$). Each DSQOLS subscale and total score showed significant improvements by 3 months, all of which were maintained at 6 and 12 months in the total sample (Table 1).

CONCLUSIONS—Among adults with type 1 diabetes undergoing skills-based training in routine U.K. health care, there was a clinically relevant improvement in HbA_{1c} in the total sample, which was, unsurprisingly, larger in those with suboptimal control (HbA_{1c} $\geq 7.5\%$) before the course. This was accompanied by significant improvement in QoL, fully maintained at 1-year follow-up, as demonstrated in previous RCTs (4) and reported from audit data (12,13). Statistically, the improvement in glycemic control was only slightly reduced by 12 months, mirroring the DAFNE RCT, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the EURODIAB cohort, and the DAFNE Database Study (2,5,6,14).

Study strengths include the observational design and relatively large numbers. Limitations include the high proportion of well-educated subjects and the lack of a control group, although the current findings reflect similar results to the DAFNE

and STTP RCTs. Limited data were available for nonrespondents who had a higher baseline HbA_{1c}.

The 0.5% reduction in HbA_{1c} by 6 months in the group with suboptimal baseline HbA_{1c} is clinically significant, reflecting a small effect size (15). The initial improvement in QoL at 3 months was equivalent to just under a medium effect size (15). The maintenance of effects from baseline to 12 months suggests that improvements in HbA_{1c} and QoL were attributable to the DAFNE intervention. The reduction in the magnitude of change relative to the original DAFNE RCT (2) may reflect the higher proportion of participants with baseline HbA_{1c} values closer to target. DAFNE audit data demonstrate significant improvements in frequency of severe hypoglycemia and hypoglycemia awareness (14). These benefits are only seen by not restricting DAFNE to people with suboptimal HbA_{1c}.

Although it seems that the effects on glycemic control attenuate somewhat with time, it is possible to achieve sustainable improvements in HbA_{1c} and QoL among adults with type 1 diabetes during routine delivery of structured education. This is encouraging given the rollout of DAFNE both nationally and internationally.

Table 1—HbA_{1c} results and DSQOLS scores across four time points

	Baseline	3 months	6 months	12 months	χ^2 test for differences between means		
					Baseline vs. first follow-up*	Baseline vs. 12 months	Follow-up comparison†
HbA_{1c} total sample							
HbA _{1c}	8.5 (1.5)	—	8.2 (1.5)	8.3 (1.6)	22.0, $df = 1$, $P < 0.001$	6.0, $df = 1$, $P < 0.05$	10.1, $df = 1$, $P < 0.001$
IFCC	70 (16)	—	66 (16)	68 (17)			
HbA_{1c} subgroup $\geq 7.5\%$ (58 mmol/mol)							
HbA _{1c}	9.1 (1.6)	—	8.6 (2.0)	8.8 (2.5)	36.8, $df = 1$, $P < 0.001$	14.8, $df = 1$, $P < 0.001$	8.5, $df = 1$, $P < 0.01$
IFCC	76 (14)	—	70 (16)	72 (17)			
DSQOLS							
Social aspects	76.8 (18.5)	81.7 (17.4)	81.6 (16.7)	80.9 (17.3)	31.6, $df = 1$, $P < 0.001$	18.5, $df = 1$, $P < 0.001$	1.2, $df = 2$, NS
Fear of hypoglycemia	69.5 (22.2)	75.0 (21.6)	75.0 (21.9)	74.4 (22.3)	23.0, $df = 1$, $P < 0.001$	14.5, $df = 1$, $P < 0.001$	0.4, $df = 2$, NS
Dietary restrictions	65.3 (23.5)	80.2 (21.9)	78.5 (21.4)	78.7 (21.1)	89.5, $df = 1$, $P < 0.001$	76.3, $df = 1$, $P < 0.001$	2.9, $df = 2$, NS
Physical complaints	72.5 (19.9)	78.1 (19.3)	79.1 (17.5)	78.2 (19.5)	32.1, $df = 1$, $P < 0.001$	25.2, $df = 1$, $P < 0.001$	2.0, $df = 2$, NS
Anxiety about the future	44.5 (27.4)	53.2 (27.2)	53.8 (26.8)	53.6 (28.2)	33.7, $df = 1$, $P < 0.001$	30.5, $df = 1$, $P < 0.001$	0.3, $df = 2$, NS
Daily hassles	56.1 (25.2)	63.1 (27.2)	64.4 (25.9)	63.9 (25.3)	21.0, $df = 1$, $P < 0.001$	27.6, $df = 1$, $P < 0.001$	1.3, $df = 2$, NS
Total score	68.3 (17.6)	75.4 (17.5)	75.5 (16.8)	75.0 (17.5)	60.6, $df = 1$, $P < 0.001$	49.3, $df = 1$, $P < 0.001$	0.7, $df = 2$, NS

Data are mean (SD). IFCC, International Federation of Clinical Chemistry and Laboratory Medicine. *Comparisons are baseline vs. 6 months for HbA_{1c} and baseline vs. 3 months for DSQOLS. †Comparison is 6 vs. 12 months for HbA_{1c}, and comparison is among 3, 6, and 12 months for DSQOLS.

Acknowledgments—This article presents independent research commissioned by the NIHR under its Program Grants for Applied Research scheme (RP-PG-0606-1184).

No potential conflicts of interest relevant to this article were reported.

D.C. researched data, contributed to the discussion, and wrote, reviewed, and edited the manuscript. M.C. researched data. R.B., J.L., D.R., S.H., M.C., and J.S. contributed to discussion and reviewed and edited the manuscript.

D.C. is the guarantor of this work and as such, had full access to all the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank all the participants who gave up their time to take part in this study.

References

1. Mühlhauser I, Jörgens V, Berger M, et al. Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. *Diabetologia* 1983;25:470–476
2. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. *BMJ* 2002;325:746–749
3. Plank J, Köhler G, Rakovac I, et al. Long-term evaluation of a structured outpatient education programme for intensified insulin therapy in patients with Type 1 diabetes: a 12-year follow-up. *Diabetologia* 2004;47:1370–1375
4. Speight J, Amiel SA, Bradley C, et al. Long-term biomedical and psychosocial outcomes following DAFNE (Dose Adjustment For Normal Eating) structured education to promote intensive insulin therapy in adults with sub-optimally controlled Type 1 diabetes. *Diabetes Res Clin Pract* 2010; 89:22–29
5. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. *JAMA* 2002;287: 2563–2569
6. Microvascular and acute complications in IDDM patients. The EURODIAB IDDM Complications Study. *Diabetologia* 1994; 37:278–285
7. Armstrong BK, White E, Saracci R. *Principles of Exposure Measurement in Epidemiology*. Oxford, U.K., Oxford University Press, 1992
8. Oliver L, Thompson G. The DAFNE Collaborative. Experiences of developing and delivering an evidenced based quality assured programme for people with Type 1 diabetes. *Pract Diabetes Int* 2009;26: 371–377
9. Bott U, Mühlhauser I, Overmann H, Berger M. Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes. *Diabetes Care* 1998;21:757–769
10. Dinneen SF, O'Hara MC, Byrne M, et al.; Irish DAFNE Study Group. The Irish DAFNE Study Protocol: a cluster randomised trial of group versus individual follow-up after structured education for Type 1 diabetes. *Trials* 2009;10:88
11. Mansell P, Chater T, Cooke D, et al. A research database for structured diabetes education (DAFNE) (Abstract). *Diabet Med* 2011;28(Suppl. 1):27
12. McIntyre HD, Knight BA, Harvey DM, Noud MN, Hagger VL, Gilshenan KS. Dose adjustment for normal eating (DAFNE) - an audit of outcomes in Australia. *Med J Aust* 2010;192:637–640
13. Sämman A, Mühlhauser I, Bender R, Kloos Ch, Müller UA. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. *Diabetologia* 2005;48:1965–1970
14. Hopkins D, Lawrence I, Mansell P, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes mellitus: the U.K. DAFNE experience. *Diabetes Care* 2012; 35:1638–1642
15. Cohen J. *Statistical power analysis for the behavioral sciences*. 2nd ed. Mahwah, New Jersey, Lawrence Erlbaum, 1988